Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020

Positive Phase 3 monarchE results to be presented in the Presidential Symposium highlight Verzenio® (abemaciclib) as the only CDK4 & 6 inhibitor to demonstrate a statistically significant reduction in the risk of cancer recurrence for people with high risk HR+, HER2- early breast cancer   Data from